The liver is the predominant site of PPARα activity and is the primary target of AFB1-generated NAFLD damage, which drives steatosis, cholestasis, and carcinogenic changes (29, 30). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.